Your browser doesn't support javascript.
loading
An extensive antigenic footprint underpins immunodominant TCR adaptability against a hypervariable viral determinant.
Nivarthi, Usha K; Gras, Stephanie; Kjer-Nielsen, Lars; Berry, Richard; Lucet, Isabelle S; Miles, John J; Tracy, Samantha L; Purcell, Anthony W; Bowden, David S; Hellard, Margaret; Rossjohn, Jamie; McCluskey, James; Bharadwaj, Mandvi.
Afiliación
  • Nivarthi UK; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria 3000, Australia;
  • Gras S; Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria 3800, Australia; Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria 3800, Australia;
  • Kjer-Nielsen L; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria 3000, Australia;
  • Berry R; Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria 3800, Australia;
  • Lucet IS; Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria 3800, Australia;
  • Miles JJ; Institute of Infection and Immunity, Cardiff University, School of Medicine, Heath Park, Cardiff CF14 4XN, United Kingdom; Queensland Institute of Medical Research Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia; School of Medicine, University of Queensland, Brisbane, Quee
  • Tracy SL; Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute for Infection and Immunity, Parkville, Victoria 3000, Australia;
  • Purcell AW; Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria 3800, Australia; Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia;
  • Bowden DS; Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute for Infection and Immunity, Parkville, Victoria 3000, Australia;
  • Hellard M; Centre for Population Health, Burnet Institute, Melbourne, Victoria 3004, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria 3800, Australia; and Centre for Research Excellence into Injecting Drug Use, Burnet Institute, Melbourne, Victoria 3004, Aus
  • Rossjohn J; Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria 3800, Australia; Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria 3800, Australia; Institute of Infection and Immu
  • McCluskey J; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria 3000, Australia; mandvi@unimelb.edu.au jamesm1@unimelb.edu.au Jamie.Rossjohn@monash.edu.
  • Bharadwaj M; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria 3000, Australia; mandvi@unimelb.edu.au jamesm1@unimelb.edu.au Jamie.Rossjohn@monash.edu.
J Immunol ; 193(11): 5402-13, 2014 Dec 01.
Article en En | MEDLINE | ID: mdl-25355921
Mutations in T cell epitopes are implicated in hepatitis C virus (HCV) persistence and can impinge on vaccine development. We recently demonstrated a narrow bias in the human TCR repertoire targeted at an immunodominant, but highly mutable, HLA-B*0801-restricted epitope ((1395)HSKKKCDEL(1403) [HSK]). To investigate if the narrow TCR repertoire facilitates CTL escape, structural and biophysical studies were undertaken, alongside comprehensive functional analysis of T cells targeted at the natural variants of HLA-B*0801-HSK in different HCV genotypes and quasispecies. Interestingly, within the TCR-HLA-B*0801-HSK complex, the TCR contacts all available surface-exposed residues of the HSK determinant. This broad epitope coverage facilitates cross-genotypic reactivity and recognition of common mutations reported in HCV quasispecies, albeit to a varying degree. Certain mutations did abrogate T cell reactivity; however, natural variants comprising these mutations are reportedly rare and transient in nature, presumably due to fitness costs. Overall, despite a narrow bias, the TCR accommodated frequent mutations by acting like a blanket over the hypervariable epitope, thereby providing effective viral immunity. Our findings simultaneously advance the understanding of anti-HCV immunity and indicate the potential for cross-genotype HCV vaccines.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Variación Antigénica / Receptores de Antígenos de Linfocitos T / Hepatitis C / Hepacivirus / Linfocitos T CD8-positivos Límite: Humans Idioma: En Revista: J Immunol Año: 2014 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Variación Antigénica / Receptores de Antígenos de Linfocitos T / Hepatitis C / Hepacivirus / Linfocitos T CD8-positivos Límite: Humans Idioma: En Revista: J Immunol Año: 2014 Tipo del documento: Article